ClinicalTrials.Veeva

Menu

Effects of Hericium Erinaceus on Microbiota and Cognition (HE)

U

University of Primorska

Status

Completed

Conditions

Cognitive Decline, Mild

Treatments

Dietary Supplement: Hericium erinaceus
Dietary Supplement: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT04939961
Hericium erinaceus

Details and patient eligibility

About

The study evaluates the effects of Hericium erinaceus on microbiota, cognition, and other health parameters in older adults. All measurements will be performed at baseline and ten weeks after daily consumptions of either Hericium erinaceus or placebo.

Full description

Hericium erinaceus, a well-known edible mushroom, has numerous biological activities. Yamabushitake (Hericium erinaceus) is a mushroom that grows on both living and dead broadleaf trees. Yamabushitake is used as food in Japan and China. Hericenones and erinacines stimulate nerve growth factor synthesis, and therefore it is expected that H. erinaceus have some effects on brain functions and autonomic nervous system. Hericium was tested in several applications, such as dementia, Alzheimer's disease, Parkinson's disease, multiple sclerosis, neuropathy and neurasthenia. The ancient Chinese knew about these possibilities and used it to support mental functions and memory, concentration. It is also very good for various digestive problems, such as gastritis, stomach ulcers, heartburn, reflux and improvement of digestion.

Therefore, the aim of our study is to evaluate the effects of Hericium erinaceus on microbiota, cognition and related parameters in elderly. The stool samples will be taken at baseline and after ten weeks of daily consumption of Hericium erinaceus or placebo. In addition, cognitive tests, anthropometric measurements, and blood analysis (lipid profile, glucose levels and neurotrophic factors) will be measured at the same time points.

Enrollment

40 patients

Sex

All

Ages

55 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age 55 - 75 years

Exclusion criteria

  • neurodegenerative disease
  • organ transplantation
  • allergy to fungi
  • antibiotic consumption in the previous 3 months

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

40 participants in 2 patient groups, including a placebo group

Hericium erinaceus
Experimental group
Description:
8 gram of mushroom Hericium erinaceus (containing 5 milligram of erinacines) per day
Treatment:
Dietary Supplement: Hericium erinaceus
Placebo capsule
Placebo Comparator group
Description:
8 gram of allergen free corn starch per day
Treatment:
Dietary Supplement: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems